Immunome (IMNM) said late Wednesday it priced an underwritten public offering of about 19.4 million shares at $7.75 per share for expected gross proceeds of $150 million.
Immunome said it has granted the underwriters a 30-day option to purchase up to an additional 2.9 million shares.
The offering is expected to close on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.